Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of LY06006 vs EU-Prolia in Postmenopausal Women with Osteoporosis
NCT05853354Phase 3Active, not recruiting
- Sponsor
- Luye Pharma Group
- Start
- Apr 2023
- Primary completion
- Jul 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of CMAB807 in postmenopausal osteoporosis, sponsored by Luye Pharma Group. Started Apr 2023; status: active, not recruiting.
02
Drugs
CMAB807
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT05853354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05853354.